In vivo binding and antitumor activity of ch 14.18

Journal of Immunotherapy

Volumn 22, Issue 5, 1999, Pages 423-430

  Kendra, Kari ^a   Malkovska, Vera ^b   Allen, Mark ^a   Guzman, Jose ^a   Albertini, Mark ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Chimeric antibody; IL 2ADCC; Melanoma; Preclinical

Indexed keywords

CH14.18; CHIMERIC ANTIBODY; INTERLEUKIN 2; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BINDING SITES, ANTIBODY; CYTOTOXICITY TESTS, IMMUNOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; MELANOMA; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED;

EID: 0032828893     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199909000-00006     Document Type: Article

References (29)

1. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high dose interleukin-2 activated killer cells for the treat ment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
2. Wawrzynczak EJ. Chapter 5: Clinical studies of antibodies. In: Antibody Therapy. Oxford: Bios Publishers, 1995:125-39.
3. Zhang S, Cordon-Cardo C, Zhang HS, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer 1997;73:42-9.
4. Houghton AN, Mintzer D, Cordon-Cardo C, et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Nat’l Acad Sci USA 1985;82:1242-6.
5. Irie RD, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986;83:8694-8.
6. Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430-40.
7. Mueller BM, Reisfeld RA, Gillies SD. Serum half-life and tumor localization of chimeric antibody deleted of CH2 domain and directed against the disialogangliosides GD2. Proc Natl Acad Sci USA 1990;87:5702-5.
8. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991;51:144-9.
9. Fulop GM, Phillips RA. The SCID mutation in mice causes a general defect in DNA repair. Nature 1990;347:479-82.
10. Hendrickson EA. The SCID mouse: relevance as an animal model system for studying human disease. Am J Pathol 1993;143:1511-22.
11. Williams SS, Alosco TR, Croy BA, Bankert RB. The study of human neoplastic disease in severe combined immunodeficient mice. Lab Anim Sci 1993; 43:139-46.
12. Mueller BM, Reisfeld RA. Potential of the SCID mouse as a host for human tumors. Cancer Metastasis Rev 1991;10:193-200.
13. Abonour R, Cigel FK, Schell K, Barnstable CS, Sabatini LM, Malkovska V. Survival and tissue distribution of human T-cell clones in SCID mice. J Immunother 1995;18:10-18.
14. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IC. The SCID-hu mouse: murine model for the analysis of human hemolymphoid differentiation. Science 1988;241:1632-9.
15. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with SCID. Nature 1988;335:256-9.
16. Pross HF, Maroun JA. The standardization of NK cell assays for use in studies of biological response modifiers. J Immunol Methods 1984;68:235-49.
17. Hank JA, Surfus J, Gan J, et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994;15:29-37.
18. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990;144:1382-6.
19. Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 1996;93:2702-7.
20. Albertini MA, Hank J, Schiller J, Kendra K, Gan J, Javorsky B, Sondel PM. Phase IB trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma [Abstract 1682], In, ASCO Proceedings. Philadelphia: Lippincott Williams & Wilkins, 1998:437a.
21. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody chi4.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 1992;3:19-24.
22. Albertini MR, Hank JA, Schiller JH. et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res 1997;3:1277-88.
23. Pancook JD, Becker JC, Gillies SD, Reisfeld RA. Eradication of human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Imunother 1996;42:88-92.
24. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991;51:144-9.
25. Von Mehren M, Weiner LM. Monoclonal antibody based therapy. Curr Opin Oncol 1996:8:493-8.
26. Berkower I. The promise and pitfalls of monoclonal antibody therapeutics. Curr Opin Biotech 1996;7:622-8.
27. Leunig M, Yuan F, Menger MD, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-60.
28. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
29. Ito T, Griffin TW, Collins JA, Brill AB. Intratumoral and wholebody distributions of Cl 10 anti-carcinoembryonic antigen radioimmunotoxin after intraperitoneal and intravenous injection: a quantitative autoradiographic study. Cancer Res 1992;52:1961-7.